Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -18.48% is 45% above its 5-year average of -33.77%, near the high end of its 5-year range (-81.28%–-15.62%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.89% above its 12-month average of -27.54%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -18.48%.
RETURN ON INVESTED CAPITAL (ROIC)
-18.48%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-27.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-28.18%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-33.77%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+32.89%
CURRENT VS 3Y AVG
+34.43%
CURRENT VS 5Y AVG
+45.29%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.61%
median of 652 covered companies
CURRENT VS SECTOR MEDIAN
+45.03%
vs the sector median at left
Dianthus Therapeutics, Inc.
Market Cap
$4.91B
Return on Invested Capital (ROIC)
-18.48%
TTM Avg
-27.54%
3Y Avg
-28.18%
5Y Avg
-33.77%
Market Cap
$4.89B
Return on Invested Capital (ROIC)
-13.88%
TTM Avg
-24.38%
3Y Avg
-22.93%
5Y Avg
-25.00%
Market Cap
$4.91B
Return on Invested Capital (ROIC)
-13.09%
TTM Avg
-9.79%
3Y Avg
-21.15%
5Y Avg
-33.38%
Market Cap
$4.75B
Return on Invested Capital (ROIC)
-23.81%
TTM Avg
-42.00%
3Y Avg
-57.33%
5Y Avg
-55.42%
Market Cap
$4.68B
Return on Invested Capital (ROIC)
3.03%
TTM Avg
-0.36%
3Y Avg
-5.28%
5Y Avg
-5.99%
Market Cap
$5.08B
Return on Invested Capital (ROIC)
5.80%
TTM Avg
5.65%
3Y Avg
5.40%
5Y Avg
4.23%
Market Cap
$4.65B
Return on Invested Capital (ROIC)
9.68%
TTM Avg
9.25%
3Y Avg
8.40%
5Y Avg
7.66%
Market Cap
$5.15B
Return on Invested Capital (ROIC)
-38.03%
TTM Avg
-36.93%
3Y Avg
-41.32%
5Y Avg
-48.18%
Market Cap
$4.62B
Return on Invested Capital (ROIC)
6.39%
TTM Avg
-7.12%
3Y Avg
-17.71%
5Y Avg
-17.71%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dianthus Therapeutics, Inc. (DNTH) | $4.91B | -18.48% | -27.54% | -28.18% | -33.77% |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.89B | -13.88% | -24.38% | -22.93% | -25.00% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.91B | -13.09% | -9.79% | -21.15% | -33.38% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.75B | -23.81% | -42.00% | -57.33% | -55.42% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 3.03% | -0.36% | -5.28% | -5.99% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.08B | 5.80% | 5.65% | 5.40% | 4.23% |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 9.68% | 9.25% | 8.40% | 7.66% |
| Erasca, Inc. (ERAS)vs › | $5.15B | -38.03% | -36.93% | -41.32% | -48.18% |
| BillionToOne, Inc. (BLLN)vs › | $4.62B | 6.39% | -7.12% | -17.71% | -17.71% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.23B | -90.04% | -83.71% | -67.61% | -57.95% |
ROIC
-18.5%
ROE
-2.5%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -18.48% |
| 2026-03-31 | -15.83% |
| 2025-12-31 | -35.57% |
| 2025-09-30 | -25.35% |
| 2025-06-30 | -42.46% |
| 2025-03-31 | -35.34% |
| 2024-12-31 | -28.65% |
| 2024-09-30 | -24.47% |
| 2024-06-30 | -19.16% |
| 2024-03-31 | -15.62% |
| 2023-12-31 | -28.38% |
| 2023-09-30 | -25.59% |
| 2023-06-30 | -51.48% |
| 2023-03-31 | -57.72% |
| 2022-12-31 | -81.28% |
| 2022-09-30 | -45.41% |
| 2022-06-30 | -48.00% |
| 2022-03-31 | -43.49% |
| 2021-12-31 | -41.71% |
| 2021-09-30 | -37.54% |
| 2021-06-30 | -35.24% |
| 2021-03-31 | -56.24% |
| 2020-12-31 | -52.40% |
| 2020-09-30 | -51.14% |
| 2020-06-30 | -49.09% |
| 2020-03-31 | -66.70% |
| 2019-12-31 | -56.29% |
| 2019-09-30 | -45.50% |
| 2019-06-30 | -37.91% |
| 2019-03-31 | -46.51% |
| 2018-12-31 | -40.82% |
| 2018-09-30 | -31.21% |
| 2018-06-30 | -23.42% |
| 2018-03-31 | -104.03% |
| 2017-12-31 | -71.00% |
